Carboplatin, French Formula

Obese correction not included

Loading...

Obese correction not included

mg/mL*min
yo

References

  1. Jennifer S Lees. Accuracy of glomerular filtration rate estimates among patients with cancer.. British journal of cancer, 2025
  2. Bram C Agema. From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology.. Drugs, 2025
  3. NA. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.. Kidney international, 2024
  4. J Herrstedt. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.. ESMO open, 2024
  5. A González-Martín. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.. Annals of oncology : official journal of the European Society for Medical Oncology, 2023
  6. R. Cathomas. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort.. Annals of oncology : official journal of the European Society for Medical Oncology, 2014
  7. M. Etienne. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.. Annals of oncology : official journal of the European Society for Medical Oncology, 2003
  8. E. Chatelut. Prediction of carboplatin clearance from standard morphological and biological patient characteristics.. Journal of the National Cancer Institute, 1995